A 36-week Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel-group, Phase 3 Clinical Trial of Sodium Oligomannate for Mild-to-Moderate Alzheimer's Dementia

Abstract

Background: New therapies are urgently needed for Alzheimer’s disease (AD). Sodium oligomannate (GV-971) is a marine-derived oligosaccharide which reconstitutes gut microbiota, reduces neuroinflammation, decreases amyloid deposition, and improves cognition in AD animal models. The first phase 3 clinical trial of GV-971 has been completed in China. Methods: We conducted a phase 3, double-blind, placebo-controlled trial in participants with mild-to-moderate AD to assess GV-971 efficacy and safety. Participants were randomized to placebo or GV-971 (900 mg) for 36 weeks. The primary outcome was the drug-placebo difference in change from baseline on the 12-item cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog12). Secondary endpoints were drug-placebo differences on the Clinician’s Interview-Based Impression of Change with caregiver input (CIBIC+), Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale, and Neuropsychiatric Inventory (NPI). Safety and tolerability were monitored. Results: 818 participants were randomized: 408 to GV-971 and 410 to placebo. A significant drug-placebo difference on the ADAS-Cog12 favoring GV-971 was present at each measurement time-point, measurable at the week 4 visit and continuing throughout the trial. The difference between groups in change from baseline was −2.15 points (95% confidence interval, −3.07 to −1.23; P<0.0001; effect size 0.531) after 36 weeks treatment. Treatment-emergent adverse event incidence was comparable between active treatment and placebo (73.9%, 75.4%). Two deaths determined to be unrelated to drug effects occurred in the GV-971 group.Conclusions: GV-971 demonstrated significant efficacy in improving cognition with sustained improvement across all observation periods of a 36-week trial. GV-971 was safe and well tolerated. Trial registration: ClinicalTrials.gov, NCT02293915. Registered on November 19, 2014.

The State of The Art on Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s Disease

“…However, thanks to such studies, neuroinflammation triggered by gut dysbiosis is now recognised as a target for the development of future therapies. 89 Currently, sodium oligomannate has completed the first phase 3 clinical trial 90 (recommended dosage: 450 mg twice a day) and represents the first new drug approved for therapeutic use since 2003. 91,92…”

Factors affecting the efficacy of repetitive transcranial magnetic stimulation for patients with Alzheimer’s disease

“…[ [3] 。针对β淀粉样蛋白的单克隆抗 体虽能降低 AD 患者的β淀粉样蛋白沉积，但并不 能改善患者的认知功能 [4][5] 。我国最新上市的甘 露特钠胶囊可能通过改变肠道菌群改善 AD 患者 的认知功能，但还需要进行更多的相关研究以证 实其疗效 [6] 。截至目前，AD 的新型药物开发几乎 都以失败告终，而传统药物的使用存在诸多限 制 [7] [11] 。目前，rTMS 在 AD 中的治疗大多选择高频。Ahmed 等 [12] 将 45…”